Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy
Public ClinicalTrials.gov record NCT04889430. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Single-arm, Open Label Trial to Evaluate Efficacy and Safety of Oral, Twice Daily LNP023 in Adult aHUS Patients Who Are Naive to Complement Inhibitor Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this Phase 3 study is to determine whether iptacopan (LNP023) is efficacious and safe for the treatment of aHUS in adult patients who are treatment naive to complement inhibitor therapy.
Study identification
- NCT ID
- NCT04889430
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 34 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 100 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 17, 2022 (Actual)
- Primary completion
- Apr 11, 2026 (Actual)
- Completion
- Apr 11, 2026 (Actual)
- Last update posted
- Aug 7, 2026
2022 – 2026
United States locations
- U.S. sites
- 16
- U.S. states
- 9
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| USC Norris Cancer Center | Los Angeles | California | 90033 | — |
| Univ of California at Los Angeles | Los Angeles | California | 90095 | — |
| Univ Cali Irvine ALS Neuromuscular | Orange | California | 92868 | — |
| Univ of California at Sacramento | Sacramento | California | 95817 | — |
| Harbor-UCLA Medical Center . | Torrance | California | 90502 | — |
| Georgetown University Lombardi Cancer Center | Washington D.C. | District of Columbia | 20007-2197 | — |
| University Of Miami | Miami | Florida | 33136 | — |
| University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| Montefiore Medical Center . | The Bronx | New York | 10461 | — |
| Montefiore Medical Center | The Bronx | New York | 10461 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| University of Cincinnati | Cincinnati | Ohio | 45267-0585 | — |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| Comprehensive Transplant Ctr at OSU | Columbus | Ohio | 43210 | — |
| UT Southwestern Medical Center | Dallas | Texas | 75390 | — |
| Virginia Commonwealth University | Richmond | Virginia | 23298 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04889430, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 7, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04889430 live on ClinicalTrials.gov.